Bio-Rad Labs (BIO) Tops Q1 EPS by $2.21

Bio-Rad Labs (NYSE: BIO) reported Q1 EPS of $5.21, $2.21 better than the analyst estimate of $3.00. Revenue for the quarter came in at $726.8 million versus the consensus estimate of $660.98 million.

2021 Financial Outlook

For the full year 2021, the company has updated its guidance and now anticipates non-GAAP currency-neutral revenue growth of approximately 5.5 to 6.0 percent and an estimated non-GAAP operating margin of approximately 17.0 percent. Management will discuss this outlook in greater detail on the first-quarter 2021 financial results conference call.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c